Evidence map›Paper›PMID 26414837›Full record

ArticleInternational surgery2015

Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma.

Hitoshi Satomura, Masanobu Nakajima, Kinro Sasaki, Satoru Yamaguchi, Yasushi Domeki, Masakazu Takahashi, Hiroto Muroi, Tsukasa Kubo, Maiko Kikuchi, Haruka Otomo and 2 more

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in International surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hitoshi SatomuraDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Masanobu NakajimaDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Kinro SasakiDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Satoru YamaguchiDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Yasushi DomekiDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Masakazu TakahashiDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Hiroto MuroiDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Tsukasa KuboDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Maiko KikuchiDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Haruka OtomoDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Keisuke IharaDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Hiroyuki KatoDepartment of Surgery I, Dokkyo Medical University, Tochigi, Japan.
Dokkyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A dose-escalation study of docetaxel (DOC), cisplatin (CDDP), and 5-fluorouracil (5-FU; DCF combination regimen) was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in advanced esophageal carcinoma. Eighteen patients with esophageal carcinoma were enrolled and received DCF combination therapy at different dose levels. DLTs included febrile neutropenia and oral mucositis. DLT occurred in 2 out of 6 patients at level 2 and 3. The study proceeded to level 4, according to the protocol. The level 4 dose was defined as the MTD and the level 3 dose was defined as the RD. The RD for DCF combination chemotherapy for advanced esophageal carcinoma in the present study was 70 mg/m(2) DOC plus 70 mg/m(2) CDDP on day 1 plus 700 mg/m(2) 5-FU on days 1-5 at 4-week intervals. This regimen was tolerable and highly active. A phase II study has been started.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinDocetaxelDose-Response Relationship, DrugEsophageal NeoplasmsFemaleFluorouracilHumansMaleMaximum Tolerated DoseMiddle AgedProspective StudiesTaxoidsCisplatinDocetaxelFluorouracilTaxoidsCisplatinDocetaxelEsophagusFluorouracilPhase I

Identifiers

PMID26414837
PMCPMC4587522
OpenAlexW3022569043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.